Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches.

ABSTRACT: Standing amidst the COVID-19 pandemic, we have faced major medical and economic crisis in recent times which remains to be an unresolved issue till date. Although the scientific community has made significant progress towards diagnosis and understanding the disease; however, effective therapeutics are still lacking. Several omics-based studies, especially proteomics and interactomics, have contributed significantly in terms of identifying biomarker panels that can potentially be used for the disease prognosis. This has also paved the way to identify the targets for drug repurposing as a therapeutic alternative. US Food and Drug Administration (FDA) has set in motion more than 500 drug development programs on an emergency basis, most of them are focusing on repurposed drugs. Remdesivir is o

SUBMITTER: Mukherjee A 

PROVIDER: S-EPMC8222565 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature